SCOPUS 정보 검색 플랫폼

Science

Volumn 348, Issue 6231, 2015, Pages 188-189

Are trade secrets delaying biosimilars?

(2) Price, W Nicholson a Rai, Arti K b

a Franklin Pierce Law Center (United States)

b DUKE UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

BIOTECHNOLOGY; COST ANALYSIS; DRUG DEVELOPMENT; INDUSTRIAL COMPETITION; INDUSTRIAL REGULATION; INNOVATION; KNOWLEDGE; MANUFACTURING; PHARMACEUTICAL INDUSTRY; REGULATORY APPROACH; RESEARCH AND DEVELOPMENT; SCIENCE AND TECHNOLOGY;

COMPETITION; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERPERSONAL COMMUNICATION; PATENT; PRIORITY JOURNAL; SHORT SURVEY; CONFIDENTIALITY; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; UNITED STATES;

UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; CONFIDENTIALITY; DRUG APPROVAL; DRUG COSTS; DRUG DISCOVERY; DRUG INDUSTRY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84927559098 PISSN: 00368075 EISSN: 10959203 Source Type: Journal
DOI: 10.1126/science.aab1684 Document Type: Short Survey

Times cited : (23)

References (12)

1
- 84927526564
- FDA Approves Zarxio, Its First Biosimilar Drug
- 6 March
- S. Tavernise, A. Pollack, FDA Approves Zarxio, Its First Biosimilar Drug, New York Times, 6 March, 2015.
- (2015) New York Times
- Tavernise, S.¹ Pollack, A.²

2
- 84922722479
- B. Falit, S. Singh, T. Brennan, Health Aff. 34, 294 (2015).
- (2015) Health Aff. , vol.34 , pp. 294
- Falit, B.¹ Singh, S.² Brennan, T.³

3
- 84902011528
- H. Grabowski, R. Guha, M. Salgado, Health Aff. 33, 1048 (2014).
- (2014) Health Aff. , vol.33 , pp. 1048
- Grabowski, H.¹ Guha, R.² Salgado, M.³

4
- 80054679577
- IMS Institute for Healthcare Informatics
- The Global Use of Medicines: Outlook Through 2016 (IMS Institute for Healthcare Informatics, 2012).
- (2012) The Global Use of Medicines: Outlook through 2016

5
- 85134999828
- CRC Press, Boca Raton, FL
- S. Ozturk, W.-S. Hu, Cell Culture Technology for Pharmaceutical and Cell-Based Therapies (CRC Press, Boca Raton, FL, 2005).
- (2005) Cell Culture Technology for Pharmaceutical and Cell-Based Therapies
- Ozturk, S.¹ Hu, W.-S.²

6
- 70449732650
- H. Li, M. d'Anjou, Curr. Opin. Biotechnol. 20, 678 (2009).
- (2009) Curr. Opin. Biotechnol. , vol.20 , pp. 678
- Li, H.¹ D'Anjou, M.²

7
- 33947660965
- B. Sharma, Biotechnol. Adv. 25, 325 (2007).
- (2007) Biotechnol. Adv. , vol.25 , pp. 325
- Sharma, B.¹

8
- 84860314070
- U.S. Food and Drug Administration, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
- (2012) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

9
- 84860303293
- U.S. Food and Drug Administration, Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (2012); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
- (2012) Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product

10
- 85031861672
- M. McCamish, G. Woollett, Clin. Pharmacol. Ther. 90, 405 (2011).
- (2011) Clin. Pharmacol. Ther. , vol.90 , pp. 405
- McCamish, M.¹ Woollett, G.²

11
- 85031859288
- Global Health Biopharm and Oncology Injectables Development, Sandoz
- Presentation to the
- M. McCamish, Global Health Biopharm and Oncology Injectables Development, Sandoz, Presentation to the Oncologic Drugs Advisory Committee, 7 January 2015.
- Oncologic Drugs Advisory Committee, 7 January 2015
- McCamish, M.¹

12
- 0004635550
- Edward Elgar, Cheltenham, UK
- D. J. Teece, Economic Performance and the Theory of the Firm (Edward Elgar, Cheltenham, UK, 1998).
- (1998) Economic Performance and the Theory of the Firm
- Teece, D.J.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.